文献速递药物不良反应与药物警戒

GSK四价灭活流感疫苗在比利时、德国和西班牙2022/2023季节的安全性增强监测

Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
PubMed 文献 · Drug Saf · 2024-06-29

本研究在比利时、德国和西班牙开展2022/2023流感季安全性增强监测,1332名接种GSK四价灭活流感疫苗者(含43名儿童)中97.8%返回不良反应卡。接种后7天内未报告与疫苗相关的严重不良事件,支持该疫苗在所有推荐年龄组中具有可接受的安全性。

要点

  • 接种后7天内未报告与GSK四价灭活流感疫苗相关的严重不良事件。
  • 第1剂后49.8%报告至少1例不良事件,最常见为注射部位疼痛(37.6%)。
  • 成人18-65岁不良事件报告率最高(59.7%),6-35月龄最低(23.5%)。

核心结论

  • 在所有年龄和严重疾病风险组中,接种后7天内未报告与GSK四价灭活流感疫苗相关的严重不良事件。
  • 研究支持并确认GSK四价灭活流感疫苗在所有推荐年龄组中具有可接受的安全性。

研究设计与样本

  • 这是一项在比利时、德国和西班牙开展的增强安全性监测研究。
  • 共1332名参与者(53.6%为女性)至少接种1剂GSK四价灭活流感疫苗,其中43名儿童接种2剂。
  • 接种者及儿童父母/监护人或法定代表被邀请填写不良反应卡,报告接种后7天内不良事件。

主要发现

  • 97.8%的不良反应卡被完成并返回。
  • 第1剂后所有年龄组中49.8%的参与者报告至少1例不良事件。
  • 第1剂后累计频率>5%的不良事件包括注射部位疼痛(37.6%)、疲劳(15.0%)、头痛(13.2%)、注射部位肿胀(9.3%)、肌痛(7.6%)和注射部位红斑(7.4%)。
  • 第1剂后不良事件报告率:18-65岁成人59.7%,3-17岁47.0%,>65岁35.7%,6-35月龄23.5%。
  • 第2剂后18.6%的参与者报告至少1例不良事件,全身性疾病和给药部位条件仍为最常见。

临床怎么用

  • 临床药师可参考本监测结果,向接种者说明接种后7天内常见不良事件以注射部位反应和全身轻度反应为主。
  • 对于儿童和成人接种者,可告知严重不良事件未报告,安全性可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal influenza is prevented through annual vaccination, especially in children and older adults. These vaccines are annually updated based on World Health Organization recommendations and require continuous safety monitoring. OBJECTIVE: We assessed the frequency and severity of adverse events within 7 days of administering GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in Belgium, Germany, and Spain during the 2022/2023 influenza season. METHODS: In this enhanced safety surveillance study, adults who received GSK's IIV4 and parents/guardians/legally acceptable representatives of vaccinated children (aged 6 months-17 years) were invited to complete adverse drug reaction cards reporting adverse events within 7 days post-vaccination. RESULTS: In total, 1332 participants (53.6% female) received at least one dose of GSK's IIV4, including 43 children who received two doses. Overall, 97.8% of adverse drug reaction cards were completed and returned in the study. All participants in Belgium were adults, while 54.7% and 7.4% in Spain and Germany, respectively, were pediatric participants aged 6 months-17 years. After Dose 1, across all age groups, 49.8% of participants reported at least one adverse event. The most common adverse events (cumulative frequency >5%) following Dose 1 were injection-site pain (37.6%), fatigue (15.0%), headache (13.2%), injection-site swelling (9.3%), myalgia (7.6%), and injection-site erythema (7.4%). Across all countries, adverse events were most common in adults aged 18-65 years (59.7%), followed by those aged 3-17 years (47.0%), >65 years (35.7%), and 6-35 months (23.5%). After Dose 2, 18.6% of participants reported at least one adverse event, with general disorders and administration site conditions again being the most frequent. CONCLUSIONS: Across all age and risk groups for serious disease, no serious adverse events related to GSK's IIV4 were reported within 7 days post-vaccination. This study supports and confirms the acceptable safety profile of GSK's IIV4 across all recommended age groups. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number: not applicable.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. de la Cueva IS, Gerber JE, Hastie A, et al. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season. Drug Saf. 2024. PMID: 38949714. doi:10.1007/s40264-024-01456-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。